Brentuximab vedotin (solution)
Based on 1 publication(s) in Google Scholar
Brentuximab vedotin (solution) (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). The antibody portion is Brentuximab (HY-P99151), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Brentuximab vedotin (solution) inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin (solution) can be used for the research of relapsed and refractory Hodgkin lymphoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.73%
- CAS No.: 914088-09-8
- Masse moléculaire:153 kDa
-
Stockage:Shipping with dry ice
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-138298
Trastuzumab deruxtecan (solution)HER2 ADC -
HY-P99016B
Enfortumab vedotin-ejfv (solution)Nectin-4 ADC -
HY-152963
Tisotumab vedotinAntibody-Drug Conjugate -
HY-138298A
Trastuzumab deruxtecanHER2 ADC -
HY-P9921A
Trastuzumab emtansine (solution)Antibody-Drug Conjugate -
HY-132253
Polatuzumab vedotinMicrotubule Inhibitor -
HY-132254A
Sacituzumab govitecan (solution)Trop-2 ADC -
HY-P3239
Belantamab mafodotinAnti-BCMA ADC -
HY-P9985
Disitamab vedotinHER2-Directed ADC -
HY-132254
Sacituzumab govitecanTrop-2 ADC -
HY-P9921
Trastuzumab emtansineAntibody-drug Conjugate -
HY-P99016A
Enfortumab vedotin-ejfvNectin-4 ADC
Publications Citing Use of MedChemExpress (MCE) Brentuximab vedotin (solution)
More
Activité biologique
Description
In Vitro
Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 914088-09-8
-
Appearance Liquid
-
Masse moléculaire 153 kDa
-
Color Colorless to light yellow
-
SMILES
[Brentuximab vedotin (solution)]
-
Livraison
Shipping with dry ice.
-
Stockage
-80°C, protect from light
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Shea L, Mehta-Shah N. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. Curr Hematol Malig Rep. 2020 Feb;15(1):9-19. [Content Brief]
[2]. Francisco JA, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Brentuximab vedotin (solution) Related Classifications
HY-P99107A Related Classifications
Powered by Bioz